Editor's key points † The evidential basis of the widespread use of corticosteroids in brain-dead organ donors was examined by the authors. † The evidence base appeared to include considerable risk of confounding, and most randomized studies had neutral results. † Observational studies appear to support the continued use of corticosteroids, but large, prospective studies of the use of corticosteroids in the management of organ donors are needed.
with a low left ventricular ejection fraction and consideration in all donors, whereas MP is recommended to all potential lung donors. 12 In contrast, American guidelines recommend administration of hormonal combination therapy to all donors. 13 However, these recommendations are based on few observational studies. 14 -17 The aim of this systematic review (SR) was to assess the clinical efficacy (haemodynamics, oxygenation, organ procurement, graft survival, and function) and safety of CSs in the management of brain-dead potential organ donors compared with placebo, standard treatments, or active comparator.
Methods

Search strategy
Randomized controlled trials (RCTs) and observational studies were identified using electronic and manual search strategies. In March 2013, MEDLINE and EMBASE were searched from the earliest accessible date. A qualified librarian reviewed the final search strategy. Terms defining the study treatments (CSs) and the study population (brain death and tissue donor) were combined. No filters were used in the search but a limit to human was applied. The bibliographies of identified studies and reviews were manually searched for additional studies. The full MEDLINE search strategy is available in Supplementary Appendix S1.
Eligibility criteria
Studies evaluating brain-dead potential organ donor patients, without age restrictions, comparing the effects of the systemic administration of any CS with those of placebo, standard treatment, or another active comparator were sought. Animal studies and case series presenting only descriptive data or lacking any comparison were excluded. Studies evaluating CS efficacy on any clinical primary or secondary outcome measures, safety, or both were included. Clinical outcomes could be evaluated on donors, recipients, or both. Studies evaluating only biochemical markers or hormone levels were excluded. There was no restriction for date and language of publication. Reasons for exclusions were documented.
Study selection
Two independent reviewers (A.J.F. and D.R.W.) screened all citations based on titles and abstracts. Full articles of selected citations were then retrieved for eligibility assessment. Disagreements were resolved by consensus.
Data extraction and validity assessment
Each study was evaluated independently and in duplicate (J.-A.A., S.D., M.D., or Z.T. and D.R.W., A.J.F., M.M.P., or K.S.). The information was collected using a pretested standardized form. A third independent reviewer (S.D. or A.J.F.) resolved any disagreement. Descriptive variables for each study (language of publication, source of funding, sample size, and study objectives) were collected. Information regarding the study population characteristics (donors and recipients when appropriate), pharmacological interventions, and outcome measures were collected and analysed. The number of organs successfully recovered and transplanted or mortality, morbidity, or both of the recipient were considered as high-impact clinical outcomes. Lower impact clinical outcomes included echocardiographic or haemodynamic changes (left ventricular ejection fraction, cardiac output, blood pressure, vasopressor, or inotrope requirements) and oxygenation status (Pa O 2 /FI O 2 ratio) in the donor. Information on all reported side effects was also collected. The risks of hyperglycaemia in the donor and HLA mismatching between the donor and the recipient were specifically evaluated. 18 19 Methodological quality was assessed using the Downs and Black scale for observational studies and the rating instrument developed by the Cochrane Handbook for Systematic Reviews of Interventions for RCTs. 20 21 Power rating in the Downs and
Black scale was not assessed because of a lack of reporting of power calculation in studies. Information regarding safety assessment method in individual studies was also collected. It was considered appropriate if side effects were prospectively collected or if they were a study endpoint. The method of assessing side effects had to be provided and its timing clinically relevant. 22 This SR was performed according to the preferred reporting items for systematic reviews and meta-analyses statement (PRISMA). 23 
Data synthesis
Sensitivity analyses were planned to evaluate the potential effect of the following subgroups on efficacy: children vs adults (16 yr of age or older), type of CS, concomitant active study treatment (vasopressin, liothyronine, or other), and year of publication. However, pooled estimates of outcome measures were not calculated because of study clinical and methodological heterogeneity.
Results
Included studies
The MEDLINEand EMBASE search strategies identified 1089 citations after duplicate removal. An additional, 15 records were identified through manual search and screened. From these, 56 full-text articles were assessed for eligibility. The SR included 11 RCTs 24 -34 and 14 were observational studies.
14 -17 35 -44 Reasons for exclusion are listed in Figure 1 . Patient characteristics of studies are listed in Tables 1 and 2 
Study population
The number of included donors in each study varied widely, and studies that measured recipient outcomes did not always report the number of donors. Patient characteristics of study population can be found in Tables 1 and 2 . Of note, variation in patient characteristics was an important source of clinical Two studies included paediatric patients although the exact number is unknown. 15 27 There was a slight male predominance in the donors when gender was reported. 15 29 30 33 34 36 37 40 -43 Only a few studies reported baseline haemodynamic 29 32 and oxygenation 16 31 43 status of the donors.
Causes of brain death included vascular injuries (nontraumatic intracranial haemorrhage), blunt or penetrating traumas, and tumours. Other causes included anoxia, central nervous system infections, or other medical causes. 29 -33 37 42 A total of 953 kidney recipients, 183 liver recipients, and 4726 heart recipients were included in this review. Five studies out of 10 evaluating outcomes on recipients reported recipients' characteristics. 14 34 44 Recipients in these studies were mostly males in their 40s. Alcoholic cirrhosis, hepatocellular carcinoma, and viral hepatitis predominated as the aetiology of end-stage liver disease in two studies. 30 Both RCTs evaluating liver recipients used two different immunosuppressive regimens: the first one combined a calcineurin inhibitor to mycophenolate mofetil and steroids without using induction therapy, 30 whereas the second one used antithymocyte globulin and high-dose dexamethasone as induction therapy followed by maintenance treatment with a calcineurin inhibitor. 34 In one recent study evaluating kidney recipients' outcome, the immunosuppressive regimen consisted of a calcineurin inhibitor-based maintenance therapy with or without induction therapy depending on different risk factors. AntiCD25s were the preferred induction agents. 33 In an older study, no induction therapy was used and the maintenance treatment consisted of azathioprine and MP. 44 
Corticosteroid dose/regimen
Most studies used MP as their CS of choice (Tables 1 and 2 30 One study used hydrocortisone 29 and two used cortisol. 17 41 Four of them did not specify any dosing of corticosteroids used in their studies. 14 15 36 40 One study compared the use of low-dose hydrocortisone consisting of a 300 mg i.v. bolus followed by 100 mg given every 8 h to high-dose MP at 15 mg kg 21 i.v.
repeated every 24 h. 43 Other treatments concomitantly permitted Co-treatments are described in Tables 1 and 2 . Thyroid hormones (either liothyronine or thyroxine), insulin, and 
Continued
Corticosteroids in the management of brain-dead potential organ donors vasopressin were sometimes administered as part of a hormonal replacement cocktail with MP. In contrast, some studies stated that insulin was administered in both groups for glucose control only, 29 -32 43 and others administered vasopressin as a vasopressor rather than for hormonal replacement. 31 32 Five studies also combined a single i.v. administration of cyclophosphamide to MP. 25 -28 44 Most of the time, all these concomitant treatments were only administered in the treatment group. A few studies also included MP as part of a more aggressive donor management protocols that were used to optimize mechanical ventilation and fluid therapy for instance. 10 35 36 Efficacy outcomes
Efficacy outcomes were divided into three categories: (1) haemodynamic and oxygenation parameters improvement, (2) organ recovery and (3) graft survival. Pooled estimates of outcome measures were planned for RCTs, they were not calculated because of significant clinical and methodological heterogeneity, although kidney graft survival was the primary outcome in six of the included RCTs and liver graft survival in two. Clinical heterogeneity resulted mostly from timing of graft survival measurement, difference in type of organ studied, and co-treatments administered. A majority of these studies were also from the 1970s and were of low quality. A summary of results is presented in Tables 1 and 2 and Figure 2 . Predetermined sensitivity analysis did not provide any further information.
Haemodynamic and oxygenation parameters
Three RCTs evaluated changes in haemodynamic parameters as their primary outcome. 29 31 32 One study concluded that hydrocortisone associated with liothyronine boluses did not result in an improved cardiac output or decreased need for dobutamine in treated donors. 29 A second study including heart donors obtained similar results. 32 The latter group also found in another trial that MP did not change the Pa O 2 /FI O 2 ratio in lung donors compared with those not receiving MP (either liothyronine or placebo), although they found in a post hoc analysis that extravascular lung water index increased less in the MP group. 
Continued
Corticosteroids in the management of brain-dead potential organ donors Seven observational studies assessed haemodynamic oroxygenation outcomes. 16 17 38 -42 Three studies found an increase either in mean arterial pressure or in cardiac output or a decrease in adrenergic or inotropic support, 17 41 42 whereas another one did not find any improvement in haemodynamics. 16 Taniguchi and colleagues found a 7-day increase in time from cerebral death until cardiac death when cortisol and liothyronine were administered to their patients. 41 Salim and colleagues showed a reduced number of donors who were lost because of cardiovascular collapse. 38 39 Two studies associated MP with an improvement in oxygenation (Pa O 2 /FI O 2 ). 16 40 Organ recovery
No RCTs directly evaluated organ recovery with CS use, although one RCT did state that there was no difference in organ recovery, without presenting any statistical comparison. 29 31 In a post hoc observational analysis of an RCT, Venkateswaran and colleagues found an increased number of lungs transplanted in those participating in the trial compared with a cohort of donors excluded from that trial. 31 Ten observational studies evaluated organ procurement as their outcomes. 15 -17 35 -40 42 Nearly all of them with the exception of one that presented neutral results 42 associated the use of CS (or a hormonal combination therapy) with an improvement in the number of organs procured.
Graft outcomes
Eight RCTs measured graft survival as their primary outcome. 24 -28 30 33 34 Two trials studying liver recipients from pretreated donors presented opposite results. 30 34 The first found a decreased rate of ischaemia -reperfusion injury defined as an increase in liver enzyme values (AST/ALT), 30 whereas the second showed that liver enzymes had a similar trajectory posttransplantation. 34 Again, Kotsch and colleagues found a decrease in the rate of grade one to three biopsyproven acute rejections within the first 6 months posttransplantation, 30 whereas Amatschek and colleagues found no difference in mortality, biopsy-proven acute rejections, or graft loss within 3 yr posttransplant. 34 The six other trials evaluating graft outcomes only included pretreated kidney donors. 24 -28 33 They all found no difference in kidney graft function or survival either at 1-week posttransplantation 33 or up to 12 months posttransplantation. 24 -28 Kidney graft failure was defined as the need for dialysis, an increase in serum creatinine, or an acute rejection. Four of these studies also used cyclophosphamide in the active treatment arm. 25 -28 Two observational studies assessed patient and graft survival. An older study evaluating kidney recipients from pretreated donors found no difference in 3-yr patient survival, but an improvement in graft survival. 44 In a large retrospective cohort study looking at heart recipients, pretreatment of donors with an hormonal combination therapy consisting of 40 Nath 2010 37 Dhar 2013 43 A A steroids, vasopressin, and thyroid hormones was associated with an improved 1 yr patient survival and a reduced odd of early graft dysfunction. 14 
Safety
Treatment safety was barely discussed in any of the randomized trials. Four studies mentioned using insulin to maintain normoglycaemia in both treatment and control groups, but did not report hyperglycaemia as a side effect. 29 -32 Only one study reported that the treatment arm required significantly more insulin to maintain normoglyacemia compared with the control group. 29 One trial comparing low-dose hydrocortisone with highdose MP assessed glycaemic control as their primary outcome. 43 They found an improvement in glycaemic target achievement 4 h after the dose was administered and an overall decrease in insulin requirements in the low-dose group. They found no difference in haemodynamics or oxygenation parameters between those two regimens, and also in lung procurement and recipient or graft survival.
Risk of bias/quality of the studies
Risks of bias of selected studies are presented in Tables 3 and 4 . Most RCTs demonstrated a high risk of bias; only three studies had an overall low level of bias. 32 -34 Allocation concealment was often not mentioned in these RCTs and six studies had no power calculation. 24 -29 Six of them did not use placebo or did not blind properly the study treatments 24 -28 30 and possible confounding biases were present in four studies. 24 28 30 31 Sequence generation was problematic in two RCTs. 25 28 One RCT based its conclusion on post hoc analyses. 31 Observational studies were also generally of poor quality. Most of these presented high risk of confounding bias or other risks of biases inherent to the study design.
Discussion
Summary of review findings
In this SR, 11 RCTs and 14 observational studies evaluating the clinical effects of CS in potential donor management were identified. No clear clinical benefit from the administration of MP to potential donors could be drawn from the RCTs. Although one low-quality RCT resulted in decreased ischaemia and reperfusion injury and in decreased biopsy-proven acute rejections in liver donors, 30 the other trials yielded neutral results.
Overall, the quality of the included RCTs was poor, with high risk of bias identified in the majority. On the other hand, multiple observational studies have found beneficial effects of CS on haemodynamic or oxygenation parameters. 16 17 41 42 Furthermore, most of these observational studies found better outcomes in organ recovery. 14 -17 35 -40 One large retrospective audit reported a positive correlation between CS administration as part of a hormonal combination therapy and increased patient and graft survivals in heart recipients from pretreated donors. 14 No meta-analysis could be performed because of significant clinical heterogeneity between studies. Clinical heterogeneity arose from included populations, treatments, clinical outcomes, and timings.
Possible mechanism of action of corticosteroids
Hypothalamic-pituitary injury occurring after brain death may be characterized by adrenal insufficiency. 3 -7 Lower levels of circulating cortisol could therefore be explained by the injury and the inability of the adrenal glands to respond adequately to stress. 6 Supplementation with stress doses of CS could theoretically improve haemodynamic stability and clinical outcomes in brain dead donors. However, as recently reported by Boonen and colleagues, the true metabolism and pharmacokinetics of cortisol in critically ill patients is not fully understood. 45 Although brain-dead organ donors were not part of this study, this may highlight the lack of understanding of the true cortisol metabolism in organ donors. Brain death is also characterized by a catecholaminergic storm in which a pro-inflammatory environment develops through release of TNF-a, IL-1, IL-6, and IL-8. These pro-inflammatory markers may be associated with poor outcomes in donors. 10 46 47 Blunting this inflammatory reaction by glucocorticoids could theoretically permit better outcomes in donors. Although it remains unclear, effects of CS could vary depending on the type of organ transplantation studied. Interestingly, one recent study compared the use of low-dose hydrocortisone with high-dose MP, 43 using the same hypothesis as in sepsis where hydrocortisone has been shown to reduce the need for vasopressors, 48 thus raising controversy regarding the optimal dosing and timing of steroids in organ donation.
Strengths and limitations
To our knowledge, this is the first SR evaluating the efficacy and safety of CS in brain-dead organ donor management. Strengths of this SR include rigorousness in methodology, assessment of the most important clinical outcomes, and focus on the quality of identified studies. Limitations include the lack of homogenous data to perform a meta-analysis and provide more objective conclusions. Decision to administer CS to the brain dead donors cannot be solely based on RCTs because of the poor quality of evidence described above. In fact, although RCTs usually provide more valuable data on patient outcomes, brain death and organ donation may be considered as a rare event, and RCTs may become less feasible and provide less convincing results. Decision to include observational studies in this SR was based on this fact, as these may become the best quality of evidence available to guide decisions made in a clinical setting of rare events. In addition, the RCTs were small and often of low methodological quality, whereas some of the observational studies were of a much larger scale.
The reason why CSs did not seem to provide any benefits in the different RCTs and were associated with better donor 49 who evaluated the efficacy of thyroid hormones on organ donor management independently from the co-administration of other hormones. They concluded that there was no clear evidence to support the routine use of thyroid hormones in the context of organ donor management. 49 An SR from Rech and colleagues also concluded that there was poor evidence to support the use of either thyroid hormones or desmopressin. 50 Although it also reviewed CSs, only three articles were included in the SR. One major difficulty in analysing the clinical effect of CSs is isolating their effects from other potentially active drugs co-administered to the patients. Studies completed in the 1970s and early 1980s combined cyclophosphamide and CS. CSs were then incorporated in hormonal regimen, which included vasopressin, insulin, and thyroid hormones. Some studies also tested a more aggressive haemodynamic management and the application of various lung protective strategies in the donor. Adequate resuscitation of patients in sepsis has already been shown to provide more benefits than most pharmacological treatments tested. 48 51 -56 The same pattern may possibly be observed in organ donor management. The multiple hormonal changes occurring after brain death may minimize the effect of the administration of a single dose of CSs. Co-administration of other hormonal therapy, although never tested in a rigorous trial, could potentially improve outcomes. For example, positive interaction of vasopressin and CS has already been described in sepsis. Their synergistic anti-inflammatory effects may be associated with improved survival. 57 Vasopressin, even if sometimes used for diabetes insipidus, could potentially improve blood pressure and reduce the need for vasopressors. Strategies to improve organ availability need to be addressed in future studies. As reported in our review and others, equipoise warrants performing a large RCT evaluating the independent components of hormone therapy, including CSs. 49 50 Most of the prospective studies in this review were single-centred, limiting the statistical power necessary to evaluate clinically relevant outcomes. An adequately powered multi-centred RCT is feasible and should evaluate the effect of CS on important clinical outcomes such as organ recovery and graft survival.
In conclusion, this SR highlights that evidence supporting the routine use of CS in the management of organ donors is conflicting and of poor quality. RCTs tend to show that the administration of CS in potential brain-dead organ donors provides no benefit, while observational studies suggest that they may be associated with improved donor and recipient outcomes. Current recommendations regarding the administration of CSs in this population originate from low-quality evidence, as observational studies do provide some evidence to support their use. 12 13 Future studies should aim at evaluating independent components of hormonotherapy, including CSs. Adequately powered multi-centred RCTs evaluating the effect of CS on clinical outcomes such as organ recovery and graft survival would be of higher impact.
